Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology

Pharmaceutics

Volumn 6, Issue 1, 2014, Pages 137-174

  Ait Oudhia, Sihem ^a   Mager, Donald E ^a   Straubinger, Robert M ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Drug delivery; Liposomes; Mathematical simulation; Nanoparticulate drug carriers; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANNAMYCIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CATIONIC LIPOSOME; CISPLATIN; CONVENTIONAL LIPOSOMES; CPX 1; CPX 351; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FIRTECAN; FLOXURIDINE; IHL 305; IMMUNOLIPOSOME; IRINOTECAN; IRINOTECAN SUCROSOFATE; JNS 002; LIPOSOME; LURTOTECAN; MBP 426; MITOPODOZIDE; MITOXANTRONE; NANOPARTICLE; NAVELBINE; NL CPT 11; OXALIPLATIN; PACLITAXEL; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PNU 93914; POLYMER; STERICALLY STABILIZED LIPOSOME; THERMODOX; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST METASTASIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; ENCAPSULATION; HUMAN; HYDROPHOBICITY; KAPOSI SARCOMA; LIPID COMPOSITION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; MEMBRANE PERMEABILITY; MENINGIOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PHASE TRANSITION; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE PROPERTY;

EID: 84897858385     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics6010137     Document Type: Review

References (191)

1. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145-160.
2. Slingerland, M.; Guchelaar, H.J.; Gelderblom, H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today 2012, 17, 160-166.
3. Drummond, D.C.; Meyer, O.; Hong, K.; Kirpotin, D.B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51, 691-743.
4. Storm, G.; ten Kate, M.T.; Working, P.K.; Bakker-Woudenberg, I.A. Doxorubicin entrapped in sterically stabilized liposomes: Effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin. Cancer Res. 1998, 4, 111-115.
5. Gregoriadis, G. Overview of liposomes. J. Antimicrob. Chemother. 1991, 28, 39-48.
6. Drummond, D.C.; Noble, C.O.; Hayes, M.E.; Park, J.W.; Kirpotin, D.B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 2008, 97, 4696-4740.
7. Oude Blenke, E.; Mastrobattista, E.; Schiffelers, R.M. Strategies for triggered drug release from tumor targeted liposomes. Expert Opin. Drug Deliv. 2013, 10, 1399-1410.
8. Li, L.; ten Hagen, T.L.; Bolkestein, M.; Gasselhuber, A.; Yatvin, J.; van Rhoon, G.C.; Eggermont, A.M.; Haemmerich, D.; Koning, G.A. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J. Control. Release 2013, 167, 130-137.
9. Li, L.; ten Hagen, T.L.; Hossann, M.; Suss, R.; van Rhoon, G.C.; Eggermont, A.M.; Haemmerich, D.; Koning, G.A. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J. Control. Release 2013, 168, 142-150.
10. Chang, H.I.; Yeh, M.K. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 2012, 7, 49-60.
11. Guo, W.; Johnson, J.L.; Khan, S.; Ahmad, A.; Ahmad, I. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetics study. Anal. Biochem. 2005, 336, 213-220.
12. Sharma, A.; Mayhew, E.; Bolcsak, L.; Cavanaugh, C.; Harmon, P.; Janoff, A.; Bernacki, R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 1997, 71, 103-107.
13. Sharma, A.; Mayhew, E.; Straubinger, R.M. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 1993, 53, 5877-5881.
14. Lim, H.J.; Masin, D.; Madden, T.D.; Bally, M.B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp Ther. 1997, 281, 566-573.
15. Forssen, E.A.; Male-Brune, R.; Adler-Moore, J.P.; Lee, M.J.; Schmidt, P.G.; Krasieva, T.B.; Shimizu, S.; Tromberg, B.J. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 1996, 56, 2066-2075.
16. Kim, E.S.; Lu, C.; Khuri, F.R.; Tonda, M.; Glisson, B.S.; Liu, D.; Jung, M.; Hong, W.K.; Herbst, R.S. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001, 34, 427-432.
17. Lu, C.; Perez-Soler, R.; Piperdi, B.; Walsh, G.L.; Swisher, S.G.; Smythe, W.R.; Shin, H.J.; Ro, J.Y.; Feng, L.; Truong, M.; et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2005, 23, 3495-3501.
18. Tardi, P.; Choice, E.; Masin, D.; Redelmeier, T.; Bally, M.; Madden, T.D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000, 60, 3389-3393.
19. Pal, A.; Khan, S.; Wang, Y.F.; Kamath, N.; Sarkar, A.K.; Ahmad, A.; Sheikh, S.; Ali, S.; Carbonaro, D.; Zhang, A.; et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 2005, 25, 331-341.
20. Emerson, D.L.; Bendele, R.; Brown, E.; Chiang, S.; Desjardins, J.P.; Dihel, L.C.; Gill, S.C.; Hamilton, M.; LeRay, J.D.; Moon-McDermott, L.; et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: A low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res. 2000, 6, 2903-2912.
21. Drummond, D.C.; Noble, C.O.; Guo, Z.; Hong, K.; Park, J.W.; Kirpotin, D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006, 66, 3271-3277.
22. Krishna, R.; Webb, M.S.; St Onge, G.; Mayer, L.D. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J. Pharmacol. Exp. Ther. 2001, 298, 1206-1212.
23. Zhigaltsev, I.V.; Maurer, N.; Akhong, Q.F.; Leone, R.; Leng, E.; Wang, J.; Semple, S.C.; Cullis, P.R. Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. J. Control. Release 2005, 104, 103-111.
24. Cosco, D.; Paolino, D.; Muzzalupo, R.; Celia, C.; Citraro, R.; Caponio, D.; Picci, N.; Fresta, M. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed. Microdevices 2009, 11, 1115-1125.
25. Storm, G.; Crommelin, D.J.A. Liposomes: Quo vadis? Pharm. Sci. Technol. Today 1998, 1, 19-31.
26. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387-6392.
27. Celia, C.; Cosco, D.; Paolino, D.; Fresta, M. Gemcitabine-loaded innovative nanocarriers vs. GEMZAR: Biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin. Drug Deliv. 2011, 8, 1609-1629.
28. Stewart, S.; Jablonowski, H.; Goebel, F.D.; Arasteh, K.; Spittle, M.; Rios, A.; Aboulafia, D.; Galleshaw, J.; Dezube, B.J. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 1998, 16, 683-691.
29. Northfelt, D.W.; Dezube, B.J.; Thommes, J.A.; Miller, B.J.; Fischl, M.A.; Friedman-Kien, A.; Kaplan, L.D.; Du Mond, C.; Mamelok, R.D.; Henry, D.H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 1998, 16, 2445-2451.
30. Cianfrocca, M.; Lee, S.; von Roenn, J.; Tulpule, A.; Dezube, B.J.; Aboulafia, D.M.; Ambinder, R.F.; Lee, J.Y.; Krown, S.E.; Sparano, J.A. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: Evidence of symptom palliation from chemotherapy. Cancer 2010, 116, 3969-3977.
31. Gordon, A.N.; Fleagle, J.T.; Guthrie, D.; Parkin, D.E.; Gore, M.E.; Lacave, A.J. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001, 19, 3312-3322.
32. Pignata, S.; Scambia, G.; Savarese, A.; Breda, E.; Sorio, R.; Pisano, C.; Lorusso, D.; Cognetti, F.; Vernaglia Lombardi, A.; Gebbia, V.; et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: Preliminary activity results of the MITO-2 phase III trial. Oncology 2009, 76, 49-54.
33. Markman, M.; Moon, J.; Wilczynski, S.; Lopez, A.M.; Rowland, K.M., Jr.; Michelin, D.P.; Lanzotti, V.J.; Anderson, G.L.; Alberts, D.S. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol. Oncol. 2010, 116, 323-325.
34. Pujade-Lauraine, E.; Wagner, U.; Aavall-Lundqvist, E.; Gebski, V.; Heywood, M.; Vasey, P.A.; Volgger, B.; Vergote, I.; Pignata, S.; Ferrero, A.; et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 2010, 28, 3323-3329.
35. Keller, A.M.; Mennel, R.G.; Georgoulias, V.A.; Nabholtz, J.M.; Erazo, A.; Lluch, A.; Vogel, C.L.; Kaufmann, M.; von Minckwitz, G.; Henderson, I.C.; et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J. Clin. Oncol. 2004, 22, 3893-3901.
36. Chan, S.; Davidson, N.; Juozaityte, E.; Erdkamp, F.; Pluzanska, A.; Azarnia, N.; Lee, L.W. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann. Oncol. 2004, 15, 1527-1534.
37. Sparano, J.A.; Makhson, A.N.; Semiglazov, V.F.; Tjulandin, S.A.; Balashova, O.I.; Bondarenko, I.N.; Bogdanova, N.V.; Manikhas, G.M.; Oliynychenko, G.P.; Chatikhine, V.A.; et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study. J. Clin. Oncol. 2009, 27, 4522-4529.
38. Alba, E.; Ruiz-Borrego, M.; Margeli, M.; Rodriguez-Lescure, A.; Sanchez-Rovira, P.; Ruiz, A.; Mel-Lorenzo, J.R.; Ramos-Vazquez, M.; Ribelles, N.; Calvo, E.; et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res. Treat. 2010, 122, 169-176.
39. Rifkin, R.M.; Gregory, S.A.; Mohrbacher, A.; Hussein, M.A. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: A Phase III multicenter randomized trial. Cancer 2006, 106, 848-858.
40. Orlowski, R.Z.; Nagler, A.; Sonneveld, P.; Blade, J.; Hajek, R.; Spencer, A.; San Miguel, J.; Robak, T.; Dmoszynska, A.; Horvath, N.; et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J. Clin. Oncol. 2007, 25, 3892-3901.
41. Sonneveld, P.; Hajek, R.; Nagler, A.; Spencer, A.; Blade, J.; Robak, T.; Zhuang, S.H.; Harousseau, J.L.; Orlowski, R.Z. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008, 112, 1529-1537.
42. Gill, P.S.; Wernz, J.; Scadden, D.T.; Cohen, P.; Mukwaya, G.M.; von Roenn, J.H.; Jacobs, M.; Kempin, S.; Silverberg, I.; Gonzales, G.; et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 1996, 14, 2353-2364.
43. Latagliata, R.; Breccia, M.; Fazi, P.; Iacobelli, S.; Martinelli, G.; di Raimondo, F.; Sborgia, M.; Fabbiano, F.; Pirrotta, M.T.; Zaccaria, A.; et al. Liposomal daunorubicin versus standard daunorubicin: Long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br. J. Haematol. 2008, 143, 681-689.
44. Glantz, M.J.; LaFollette, S.; Jaeckle, K.A.; Shapiro, W.; Swinnen, L.; Rozental, J.R.; Phuphanich, S.; Rogers, L.R.; Gutheil, J.C.; Batchelor, T.; et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 1999, 17, 3110-3116.
45. Booser, D.J.; Esteva, F.J.; Rivera, E.; Valero, V.; Esparza-Guerra, L.; Priebe, W.; Hortobagyi, G.N. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother. Pharmacol. 2002, 50, 6-8.
46. Wetzler, M.; Thomas, D.A.; Wang, E.S.; Shepard, R.; Ford, L.A.; Heffner, T.L.; Parekh, S.; Andreeff, M.; O'Brien, S.; Kantarjian, H.M. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 2013, 13, 430-434.
47. Harrington, K.J.; Lewanski, C.R.; Northcote, A.D.; Whittaker, J.; Wellbank, H.; Vile, R.G.; Peters, A.M.; Stewart, J.S. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 2001, 12, 493-496.
48. Seetharamu, N.; Kim, E.; Hochster, H.; Martin, F.; Muggia, F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res. 2010, 30, 541-545.
49. White, S.C.; Lorigan, P.; Margison, G.P.; Margison, J.M.; Martin, F.; Thatcher, N.; Anderson, H.; Ranson, M. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br. J. Cancer 2006, 95, 822-828.
50. Stathopoulos, G.P.; Antoniou, D.; Dimitroulis, J.; Stathopoulos, J.; Marosis, K.; Michalopoulou, P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother. Pharmacol. 2011, 68, 945-950.
51. De Jonge, M.J.; Slingerland, M.; Loos, W.J.; Wiemer, E.A.; Burger, H.; Mathijssen, R.H.; Kroep, J.R.; den Hollander, M.A.; van der Biessen, D.; Lam, M.H.; et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer 2010, 46, 3016-3021.
52. Dragovich, T.; Mendelson, D.; Kurtin, S.; Richardson, K.; von Hoff, D.; Hoos, A. A Phase II trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother. Pharmacol. 2006, 58, 759-764.
53. Celsion coporation. Available online: http://celsion.com/docs/technology_thermodox (accessed on 10 March 2014).
54. Katsumata, N.; Fujiwara, Y.; Kamura, T.; Nakanishi, T.; Hatae, M.; Aoki, D.; Tanaka, K.; Tsuda, H.; Kamiura, S.; Takehara, K.; et al. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: A Phase II study of the Japanese Gynecologic Oncology Group. Jpn. J. Clin. Oncol. 2008, 38, 777-785.
55. Duffaud, F.; Borner, M.; Chollet, P.; Vermorken, J.B.; Bloch, J.; Degardin, M.; Rolland, F.; Dittrich, C.; Baron, B.; Lacombe, D.; et al. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC new drug development group study. Eur. J. Cancer 2004, 40, 2748-2752.
56. Gokhale, P.C.; Pei, J.; Zhang, C.; Ahmad, I.; Rahman, A.; Kasid, U. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res. 2001, 21, 3313-3321.
57. Infante, J.R.; Keedy, V.L.; Jones, S.F.; Zamboni, W.C.; Chan, E.; Bendell, J.C.; Lee, W.; Wu, H.; Ikeda, S.; Kodaira, H.; et al. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2012, 70, 699-705.
58. Roy, A.C.; Park, S.R.; Cunningham, D.; Kang, Y.K.; Chao, Y.; Chen, L.T.; Rees, C.; Lim, H.Y.; Tabernero, J.; Ramos, F.J.; et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann. Oncol. 2013, 24, 1567-1573.
59. Senzer, N.M.; Matsuno, K.; Yamagata, N.; Fujisawa, T.; Wasserman, E.; Sutherland, W.; Sharma, S.; Phan, A. MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics. Mol. Cancer Ther. 2009, 8, 12-19.
60. Rodriguez, M.A.; Pytlik, R.; Kozak, T.; Chhanabhai, M.; Gascoyne, R.; Lu, B.; Deitcher, S.R.; Winter, J.N. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: Report of the pivotal phase II study. Cancer 2009, 115, 3475-3482.
61. Batist, G.; Gelmon, K.A.; Chi, K.N.; Miller, W.H., Jr.; Chia, S.K.; Mayer, L.D.; Swenson, C.E.; Janoff, A.S.; Louie, A.C. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15, 692-700.
62. Feldman, E.J.; Lancet, J.E.; Kolitz, J.E.; Ritchie, E.K.; Roboz, G.J.; List, A.F.; Allen, S.L.; Asatiani, E.; Mayer, L.D.; Swenson, C.; et al. First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 2011, 29, 979-985.
63. Young, R.C.; Ozols, R.F.; Myers, C.E. The anthracycline antineoplastic drugs. N. Engl. J. Med. 1981, 305, 139-153.
64. Nichols, J.W.; Deamer, D.W. Catecholamine uptake and concentration by liposomes maintaining pH gradients. Biochim. Biophys. Acta 1976, 455, 269-271.
65. Mayer, L.D.; Bally, M.B.; Hope, M.J.; Cullis, P.R. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim. Biophys. Acta 1985, 816, 294-302.
66. Madden, T.D.; Harrigan, P.R.; Tai, L.C.; Bally, M.B.; Mayer, L.D.; Redelmeier, T.E.; Loughrey, H.C.; Tilcock, C.P.; Reinish, L.W.; Cullis, P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chem. Phys. Lipids 1990, 53, 37-46.
67. Lasic, D.D.; Frederik, P.M.; Stuart, M.C.; Barenholz, Y.; McIntosh, T.J. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. 1992, 312, 255-258.
68. Haran, G.; Cohen, R.; Bar, L.K.; Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1993, 1151, 201-215.
69. Cullis, P.R.; Hope, M.J.; Bally, M.B.; Madden, T.D.; Mayer, L.D.; Fenske, D.B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta 1997, 1331, 187-211.
70. Zucker, D.; Marcus, D.; Barenholz, Y.; Goldblum, A. Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties. J. Control. Release 2009, 139, 73-80.
71. Charrois, G.J.; Allen, T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta 2004, 1663, 167-177.
72. Johnston, M.J.; Edwards, K.; Karlsson, G.; Cullis, P.R. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J. Liposome Res. 2008, 18, 145-157.
73. Laginha, K.M.; Verwoert, S.; Charrois, G.J.; Allen, T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin. Cancer Res. 2005, 11, 6944-6949.
74. Lim, H.J.; Masin, D.; McIntosh, N.L.; Madden, T.D.; Bally, M.B. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J. Pharmacol. Exp. Ther. 2000, 292, 337-345.
75. Ishida, T.; Harashima, H.; Kiwada, H. Liposome clearance. Biosci. Rep. 2002, 22, 197-224.
76. Moghimi, S.M.; Hunter, A.C.; Andresen, T.L. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 481-503.
77. Senior, J.H. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3, 123-193.
78. Weinstein, J.N. Liposomes as drug carriers in cancer therapy. Cancer Treat. Rep. 1984, 68, 127-135.
79. Gregoriadis, G. The carrier potential of liposomes in biology and medicine (second of two parts). N. Engl. J. Med. 1976, 295, 765-770.
80. Gregoriadis, G. The carrier potential of liposomes in biology and medicine (first of two parts). N. Engl. J. Med. 1976, 295, 704-710.
81. Patel, H.M. Influence of lipid composition on opsonophagocytosis of liposomes. Res. Immunol. 1992, 143, 242-244.
82. Devine, D.V.; Marjan, J.M. The role of immunoproteins in the survival of liposomes in the circulation. Crit. Rev. Ther. Drug Carrier Syst. 1997, 14, 105-131.
83. Ohlson, M.; Sorensson, J.; Haraldsson, B. Glomerular size and charge selectivity in the rat as revealed by FITC-ficoll and albumin. Am. J. Physiol. Renal Physiol. 2000, 279, F84-F91.
84. Lund, U.; Rippe, A.; Venturoli, D.; Tenstad, O.; Grubb, A.; Rippe, B. Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. Am. J. Physiol. Renal Physiol. 2003, 284, F1226-F1234.
85. Allen, T.M.; Cheng, W.W.; Hare, J.I.; Laginha, K.M. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med. Chem. 2006, 6, 513-523.
86. Adlakha-Hutcheon, G.; Bally, M.B.; Shew, C.R.; Madden, T.D. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat. Biotechnol. 1999, 17, 775-779.
87. Hitzman, C.J.; Wiedmann, T.S.; Dai, H.; Elmquist, W.F. Measurement of drug release from microcarriers by microdialysis. J. Pharm. Sci. 2005, 94, 1456-1466.
88. Musteata, F.M.; Pawliszyn, J.; Qian, M.G.; Wu, J.T.; Miwa, G.T. Determination of drug plasma protein binding by solid phase microextraction. J. Pharm. Sci. 2006, 95, 1712-1722.
89. Webb, M.S.; Harasym, T.O.; Masin, D.; Bally, M.B.; Mayer, L.D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 1995, 72, 896-904.
90. Bulitta, J.B.; Zhao, P.; Arnold, R.D.; Kessler, D.R.; Daifuku, R.; Pratt, J.; Luciano, G.; Hanauske, A.R.; Gelderblom, H.; Awada, A.; et al. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother. Pharmacol. 2009, 63, 1049-1063.
91. Kagan, L.; Gershkovich, P.; Wasan, K.M.; Mager, D.E. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone(R): Pooled analysis of published data. AAPS J. 2011, 13, 255-264.
92. Jain, R.K. Transport of molecules in the tumor interstitium: A review. Cancer Res. 1987, 47, 3039-3051.
93. Jain, R.K. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J. Natl. Cancer Inst. 1989, 81, 570-576.
94. Jain, R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990, 9, 253-266.
95. Jain, R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990, 50, 814-819.
96. Papahadjopoulos, D.; Allen, T.M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, S.K.; Lee, K.D.; Woodle, M.C.; Lasic, D.D.; Redemann, C.; et al. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 1991, 88, 11460-11464.
97. Yuan, F.; Leunig, M.; Huang, S.K.; Berk, D.A.; Papahadjopoulos, D.; Jain, R.K. Microvascular permeability and interstitial penetration of sterically stabilized (STEALTH) liposomes in a human tumor xenograft. Cancer Res. 1994, 54, 3352-3356.
98. Jain, R.K. Delivery of molecular medicine to solid tumors. Science 1996, 271, 1079-1080.
99. Yuan, F.; Salehi, H.A.; Boucher, Y.; Vasthare, U.S.; Tuma, R.F.; Jain, R.K. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 1994, 54, 4564-4568.
100. Seymour, L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9, 135-187.
101. Huang, S.K.; Martin, F.J.; Jay, G.; Vogel, J.; Papahadjopoulos, D.; Friend, D.S. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol. 1993, 143, 10-14.
102. Sarti, P.; Ginobbi, P.; D'Agostino, I.; Arancia, G.; Lendaro, E.; Molinari, A.; Ippoliti, R.; Citro, G. Liposomal targeting of leukaemia HL60 cells induced by transferrin-receptor endocytosis. Biotechnol. Appl. Biochem. 1996, 24, 269-276.
103. Park, J.W.; Hong, K.; Carter, P.; Asgari, H.; Guo, L.Y.; Keller, G.A.; Wirth, C.; Shalaby, R.; Kotts, C.; Wood, W.I.; et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 1995, 92, 1327-1331.
104. Straubinger, R.M.; Hong, K.; Friend, D.S.; Papahadjopoulos, D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles. Cell 1983, 32, 1069-1079.
105. Heath, T.; Lopez, N.; Stern, W.; Papahadjopoulos, D. 5-Fluoroorotate: A new liposome-dependent cytotoxic agent. FEBS Lett. 1985, 187, 73-75.
106. Heath, T.D.; Brown, C.S. Liposome dependent delivery of N-phosphonacetyl-L-aspartic acid to cells in vitro. J. Liposome Res. 1989, 1, 303-317.
107. Matthay, K.K.; Abai, A.M.; Cobb, S.; Hong, K.; Papahadjopoulos, D.; Straubinger, R.M. Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res. 1989, 49, 4879-4886.
108. Kirpotin, D.B.; Drummond, D.C.; Shao, Y.; Shalaby, M.R.; Hong, K.; Nielsen, U.B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66, 6732-6740.
109. Drummond, D.C.; Noble, C.O.; Guo, Z.; Hayes, M.E.; Connolly-Ingram, C.; Gabriel, B.S.; Hann, B.; Liu, B.; Park, J.W.; Hong, K.; et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J. Control. Release 2010, 141, 13-21.
110. Hendriks, B.S.; Klinz, S.G.; Reynolds, J.G.; Espelin, C.W.; Gaddy, D.F.; Wickham, T.J. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: Multiple low-affinity interactions lead to a threshold effect. Mol. Cancer Ther. 2013, 12, 1816-1828.
111. Connor, J.; Huang, L. Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes. J. Cell Biol. 1985, 101, 582-589.
112. Straubinger, R.M.; Düzgünes, N.; Papahadjopoulos, D. pH-Sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. 1985, 179, 148-154.
113. Chu, C.-J.; Dijkstra, J.; Lai, M.-Z.; Hong, K.; Szoka, F.C., Jr. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm. Res. 1990, 7, 824-834.
114. Heath, T.; Montgomery, J.; Piper, J.; Papahadjopoulos, D. Antibody-targeted liposomes: Increase in specific toxicity of methotrexate-g-aspartate. Proc. Natl. Acad. Sci. USA. 1983, 80, 1377-1381.
115. Charrois, G.J.; Allen, T.M. Rate of biodistribution of STEALTH liposomes to tumor and skin: Influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim. Biophys. Acta 2003, 1609, 102-108.
116. Nagayasu, A.; Uchiyama, K.; Kiwada, H. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 1999, 40, 75-87.
117. Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95, 4607-4612.
118. Allen, T.M.; Hansen, C.; Rutledge, J. Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 1989, 981, 27-35.
119. Woodle, M.C.; Matthay, K.K.; Newman, M.S.; Hidayat, J.E.; Collins, L.R.; Redemann, C.; Martin, F.J.; Papahadjopoulos, D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1105, 193-200.
120. Gabizon, A.; Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 1988, 85, 6949-6953.
121. Allen, T.M.; Chonn, A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987, 223, 42-46.
122. Eastman, S.J.; Wilschut, J.; Cullis, P.R.; Hope, M.J. Intervesicular exchange of lipids with weak acid and weak base characteristics: Influence of transmembrane pH gradients. Biochim. Biophys. Acta 1989, 981, 178-184.
123. Mayhew, E.; Ito, M.; Lazo, R. Toxicity of non-drug-containing liposomes for cultured human cells. Exp. Cell Res. 1987, 171, 195-202.
124. Senior, J.H.; Trimble, K.R.; Maskiewicz, R. Interaction of positively-charged liposomes with blood: Implications for their application in vivo. Biochim. Biophys. Acta 1991, 1070, 173-179.
125. Gabizon, A.; Papahadjopoulos, D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta 1992, 1103, 94-100.
126. Litzinger, D.C.; Brown, J.M.; Wala, I.; Kaufman, S.A.; Van, G.Y.; Farrell, C.L.; Collins, D. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta 1996, 1281, 139-149.
127. Thurston, G.; McLean, J.W.; Rizen, M.; Baluk, P.; Haskell, A.; Murphy, T.J.; Hanahan, D.; McDonald, D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Investig. 1998, 101, 1401-1413.
128. Campbell, R.B.; Fukumura, D.; Brown, E.B.; Mazzola, L.M.; Izumi, Y.; Jain, R.K.; Torchilin, V.P.; Munn, L.L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002, 62, 6831-6836.
129. Senior, J.; Gregoriadis, G. Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components. Life Sci. 1982, 30, 2123-2136.
130. Gregoriadis, G.; Davis, C. Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. Biochem. Biophys. Res. Commun. 1979, 89, 1287-1293.
131. Allen, T.M.; Hansen, C.; Martin, F.; Redemann, C.; Yau-Young, A. Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066, 29-36.
132. Daemen, T.; Hofstede, G.; Ten Kate, M.T.; Bakker-Woudenberg, I.A.; Scherphof, G.L. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer 1995, 61, 716-721.
133. Woodle, M.C.; Lasic, D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113, 171-199.
134. Hong, K.; Kirpotin, D.B.; Park, J.W.; Shao, Y.; Shalaby, R.; Colbern, G.; Benz, C.C.; Papahadjopoulos, D. Anti-HER2 immunoliposomes for targeted drug delivery. Ann. N. Y. Acad. Sci. 1999, 886, 293-296.
135. Sapra, P.; Allen, T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002, 62, 7190-7194.
136. Sugano, M.; Egilmez, N.K.; Yokota, S.J.; Chen, F.A.; Harding, J.; Huang, S.K.; Bankert, R.B. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 2000, 60, 6942-6949.
137. Nielsen, U.B.; Kirpotin, D.B.; Pickering, E.M.; Hong, K.; Park, J.W.; Refaat Shalaby, M.; Shao, Y.; Benz, C.C.; Marks, J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 2002, 1591, 109-118.
138. Lopes de Menezes, D.E.; Pilarski, L.M.; Allen, T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998, 58, 3320-3330.
139. Park, J.W.; Hong, K.; Kirpotin, D.B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Moore, D.; et al. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8, 1172-1181.
140. Mamot, C.; Drummond, D.C.; Noble, C.O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D.B.; Park, J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65, 11631-11638.
141. Heath, T.D.; Fraley, R.T.; Bentz, J.; Voss, E.W., Jr.; Herron, J.N.; Papahadjopoulos, D. Antibody-directed liposomes. Determination of affinity constants for soluble and liposome-bound antifluorescein. Biochim. Biophys. Acta 1984, 770, 148-158.
142. Allen, T.M.; Newman, M.S.; Woodle, M.C.; Mayhew, E.; Uster, P.S. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer 1995, 62, 199-204.
143. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42, 463-478.
144. Zhou, R.; Mazurchuk, R.; Straubinger, R.M. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. 2002, 62, 2561-2566.
145. Laverman, P.; Brouwers, A.H.; Dams, E.T.; Oyen, W.J.; Storm, G.; van Rooijen, N.; Corstens, F.H.; Boerman, O.C. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J. Pharmacol. Exp. Ther. 2000, 293, 996-1001.
146. Ishida, T.; Ichihara, M.; Wang, X.; Yamamoto, K.; Kimura, J.; Majima, E.; Kiwada, H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 2006, 112, 15-25.
147. Ishida, T.; Atobe, K.; Wang, X.; Kiwada, H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: Effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 2006, 115, 251-258.
148. Ishida, T.; Maeda, R.; Ichihara, M.; Irimura, K.; Kiwada, H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 2003, 88, 35-42.
149. Gabizon, A.; Shiota, R.; Papahadjopoulos, D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 1989, 81, 1484-1488.
150. Lyass, O.; Uziely, B.; Ben-Yosef, R.; Tzemach, D.; Heshing, N.I.; Lotem, M.; Brufman, G.; Gabizon, A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89, 1037-1047.
151. Lorusso, D.; di Stefano, A.; Carone, V.; Fagotti, A.; Pisconti, S.; Scambia, G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ("hand-foot" syndrome). Ann. Oncol. 2007, 18, 1159-1164.
152. Arnold, R.D.; Mager, D.E.; Slack, J.E.; Straubinger, R.M. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin. Cancer Res. 2005, 11, 8856-8865.
153. Ait-Oudhia, S.; Straubinger, R.M.; Mager, D.E. Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J. Pharmacol. Exp. Ther. 2013, 344, 103-112.
154. Jang, S.H.; Wientjes, M.G.; Au, J.L. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J. Pharmacol. Exp. Ther. 2001, 296, 1035-1042.
155. Xiong, X.B.; Huang, Y.; Lu, W.L.; Zhang, H.; Zhang, X.; Zhang, Q. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm. Res. 2005, 22, 933-939.
156. Harashima, H.; Tsuchihashi, M.; Iida, S.; Doi, H.; Kiwada, H. Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. Adv. Drug Deliv. Rev. 1999, 40, 39-61.
157. Harashima, H.; Iida, S.; Urakami, Y.; Tsuchihashi, M.; Kiwada, H. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J. Control. Release 1999, 61, 93-106.
158. Hendriks, B.S.; Reynolds, J.G.; Klinz, S.G.; Geretti, E.; Lee, H.; Leonard, S.C.; Gaddy, D.F.; Espelin, C.W.; Nielsen, U.B.; Wickham, T.J. Multiscale kinetic modeling of liposomal doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. Clin. Pharmacol. Ther. 2012, 1, 1-11.
159. Ait-Oudhia, S.; Straubinger, R.M.; Mager, D.E. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm. Res. 2012, 29, 2833-2844.
160. Mayer, L.D.; Bally, M.B.; Cullis, P.R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 1986, 857, 123-126.
161. Harrigan, P.R.; Wong, K.F.; Redelmeier, T.E.; Wheeler, J.J.; Cullis, P.R. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH-gradients. Biochim. Biophys. Acta 1993, 1149, 329-348.
162. Oh, Y.-K.; Straubinger, R.M. Cellular retention of liposome-delivered compounds modulated by a probenecid-sensitive anion transporter. Pharm. Res. 1997, 14, 1203-1209.
163. Straubinger, R.M.; Lopez, N.G.; Debs, R.; Hong, K.; Papahadjopoulos, D. Liposome-based therapy of human ovarian cancer: Parameters determining potency of negatively-charged and antibody-targeted liposomes. Cancer Res. 1988, 48, 5237-5245.
164. Paolino, D.; Cosco, D.; Racanicchi, L.; Trapasso, E.; Celia, C.; Iannone, M.; Puxeddu, E.; Costante, G.; Filetti, S.; Russo, D.; et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs. GEMZAR: Biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Control. Release 2010, 144, 144-150.
165. Pattillo, C.B.; Sari-Sarraf, F.; Nallamothu, R.; Moore, B.M.; Wood, G.C.; Kiani, M.F. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm. Res. 2005, 22, 1117-1120.
166. Mori, A.; Kennel, S.J.; van Borssum Waalkes, M.; Scherphof, G.L.; Huang, L. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model. Cancer Chemother. Pharmacol. 1995, 35, 447-456.
167. Talbott, C.M.; Vorobyov, I.; Borchman, D.; Taylor, K.G.; DuPre, D.B.; Yappert, M.C. Conformational studies of sphingolipids by NMR spectroscopy. II. Sphingomyelin. Biochim. Biophys. Acta 2000, 1467, 326-337.
168. Allen, T.M.; Mumbengegwi, D.R.; Charrois, G.J. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin. Cancer Res. 2005, 11, 3567-3573.
169. Working, P.K.; Dayan, A.D. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). Hum. Exp. Toxicol. 1996, 15, 751-785.
170. Hong, R.L.; Huang, C.J.; Tseng, Y.L.; Pang, V.F.; Chen, S.T.; Liu, J.J.; Chang, F.H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 1999, 5, 3645-3652.
171. Gabizon, A.; Martin, F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997, 54, 15-21.
172. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin. Pharmacokinet. 2003, 42, 419-436.
173. Working, P.K.; Newman, M.S.; Sullivan, T.; Yarrington, J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J. Pharmacol. Exp. Ther. 1999, 289, 1128-1133.
174. Jain, R.K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7, 653-664.
175. Minchinton, A.I.; Tannock, I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 2006, 6, 583-592.
176. Baxter, L.T.; Zhu, H.; Mackensen, D.G.; Butler, W.F.; Jain, R.K. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995, 55, 4611-4622.
177. Mager, D.E.; Jusko, W.J. Development of translational pharmacokinetic-pharmacodynamic models. Clin. Pharmacol. Ther. 2008, 83, 909-912.
178. El-Kareh, A.W.; Secomb, T.W. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2000, 2, 325-338.
179. Gianni, L.; Kearns, C.M.; Giani, A.; Capri, G.; Vigano, L.; Lacatelli, A.; Bonadonna, G.; Egorin, M.J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 1995, 13, 180-190.
180. Griffon-Etienne, G.; Boucher, Y.; Brekken, C.; Suit, H.D.; Jain, R.K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications. Cancer Res. 1999, 59, 3776-3782.
181. Lu, D.; Wientjes, M.G.; Lu, Z.; Au, J.L. Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 2007, 322, 80-88.
182. Aroui, S.; Brahim, S.; de Waard, M.; Breard, J.; Kenani, A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett. 2009, 285, 28-38.
183. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D.; et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12, 1317-1324.
184. Milas, L.; Hunter, N.R.; Kurdoglu, B.; Mason, K.A.; Meyn, R.E.; Stephens, L.C.; Peters, L.J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol. 1995, 35, 297-303.
185. Sparreboom, A.; van Tellingen, O.; Nooijen, W.J.; Beijnen, J.H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996, 56, 2112-2115.
186. Ah-See, M.L.; Makris, A.; Taylor, N.J.; Harrison, M.; Richman, P.I.; Burcombe, R.J.; Stirling, J.J.; d'Arcy, J.A.; Collins, D.J.; Pittam, M.R.; et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 2008, 14, 6580-6589.
187. 1H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magn. Reson. Imaging 2008, 26, 523-531.
188. Yankeelov, T.E.; Lepage, M.; Chakravarthy, A.; Broome, E.E.; Niermann, K.J.; Kelley, M.C.; Meszoely, I.; Mayer, I.A.; Herman, C.R.; McManus, K.; et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: Initial results. Magn. Reson. Imaging 2007, 25, 1-13.
189. Eytan, G.D.; Kuchel, P.W. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int. Rev. Cytol. 1999, 190, 175-250.
190. Baxter, L.T.; Zhu, H.; Mackensen, D.G.; Jain, R.K. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994, 54, 1517-1528.
191. Stewart, D.J. Making and using DNA microarrays: A short course at Cold Spring Harbor Laboratory. Genome Res. 2000, 10, 1-3.